Health ministry invites suggestions for renaming drug regulator CDSCO

New Delhi: The Union Health Ministry has invited suggestions for renaming the country’s drug regulator CDSCO in line with its expanded roles. In a public notice issued Thursday, the Central Drugs Standard Control Organisation (CDSCO) said its name was given keeping its role when it was created, but the present nomenclature was not reflecting its roles and responsibilities.

The notice said the role of CDSCO has expanded to several areas, including regulation of new drugs, vaccines and clinical trials, all imports pertaining to drugs, medical devices and cosmetics, Central Licensing Approval Authority for blood banks and vaccines, setting of standards under the Drugs and Cosmetics Act, 1940, among others.

It said R A Mashelkar in his report recommended creation of National Drug Authority (NDA) or Central Drug Authority (CDA).

The Drugs Technical Advisory Board (DTAB) in its 75th meeting held on January 3, 2017 had recommended renaming CDSCO as Indian Drugs Administration, the notice said, adding other name suggestions include Indian Medical Products Administration.

“In view of the above, it was decided to rename CDSCO and also have a new logo of its own. The new name should reflect the current role and encompass the areas administered by it.

“All the stakeholders are requested to send their suggestions/comments on the new name and the design,” the notice to various stakeholders, state drug controllers, pharma associations, said.

The ministry added that the suggestions should be submitted within two weeks from the date of the notice.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert